Ra Pharmaceuticals (Ra Pharmaceuticals) EPS (Basic) : $-2.31 (TTM As of Dec. 2019)

View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals EPS (Basic)?

Ra Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2019 was $-0.79. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2019 was $-2.31.

Ra Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2019 was $-0.79. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2019 was $-2.31.

Ra Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2019 was $-0.79. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2019 was -2.31.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Ra Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Ra Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals EPS (Basic) Chart

Ra Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EPS (Basic)

Get a 7-Day Free Trial

-1.17

-6.98

-2.41

-2.06

-2.31

Ra Pharmaceuticals Quarterly Data
	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
EPS (Basic)	Get a 7-Day Free Trial														-0.46	-0.45	-0.52	-0.55	-0.79

Ra Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ra Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2019 is calculated as

Basic EPS (A: Dec. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-102.688	-	0)	/	44.363
	=	-2.31

Ra Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2019 is calculated as

Basic EPS (Q: Dec. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-36.777	-	0)	/	47.198
	=	-0.78

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31

Ra Pharmaceuticals (NAS:RARX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ra Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

87 Cambridge Park Drive, Cambridge, MA, USA, 02140

Website

http://www.rapharma.com

Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.

Executives

Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco	director, officer: President and CEO	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins	10 percent owner
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner	officer: Executive VP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472